Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation

Código QR

Predictive Factors And Long-Term Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment Of Retinal Angiomatous Proliferation

Maiko Maruyama-Inoue, Shimpei Sato, Shin Yamane, Kazuaki Kadonosono Department of Ophthalmology, Yokohama City University Medical Center, Yokohama, JapanCorrespondence: Maiko Maruyama-InoueDepartment of Ophthalmology, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama, Ka...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maruyama-Inoue M, Sato S, Yamane S, Kadonosono K
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	ranibizumab aflibercept retinal angiomatous proliferation age-related macular degeneration intravitreal injection Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/a86303419e6a445ba6f68caf68b45e2b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ranibizumab in monotherapy and combined with photodynamic therapy for retinal angiomatous proliferation
por: Arias L, et al.
Publicado: (2016)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
por: Fouda SM, et al.
Publicado: (2017)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
por: Xiu-Xian Wang, et al.
Publicado: (2021)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
por: Nudleman E, et al.
Publicado: (2016)

Evaluation of peripheral fundus autofluorescence in eyes with wet age-related macular degeneration
por: Suetsugu T, et al.
Publicado: (2016)

Adding a Corticosteroid or Switching to Another Anti-VEGF in Insufficiently Responsive Wet Age-Related Macular Degeneration
por: Kaya C, et al.
Publicado: (2019)

Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center
por: Jang K, et al.
Publicado: (2020)

Visual acuity loss associated with excessive “dry macula” in exudative age-related macular degeneration
por: Takahashi H, et al.
Publicado: (2018)

Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
por: Sakanishi Y, et al.
Publicado: (2017)

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
por: Tagami M, et al.
Publicado: (2017)

Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
por: Sivaprasad S, et al.
Publicado: (2016)

Treatment of Macular Edema in Vascular Retinal Diseases: A 2021 Update
por: Andrzej Grzybowski, et al.
Publicado: (2021)

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
por: Ivanovska Adjievska B, et al.
Publicado: (2017)

Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
por: Mehta H, et al.
Publicado: (2020)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
por: Nixon DR, et al.
Publicado: (2017)

Prefilled syringes for intravitreal drug delivery
por: Sassalos TM, et al.
Publicado: (2019)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
por: Garweg JG
Publicado: (2019)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
por: Hirakata T, et al.
Publicado: (2016)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
por: Khanani AM, et al.
Publicado: (2019)

Clinical Experience in the Administration of Intravitreal Injection Therapy at a Tertiary University Hospital in Jordan During the COVID-19 Lockdown
por: Saleh OA, et al.
Publicado: (2020)

Impact of injection therapy on retinal patients with diabetic macular edema or retinal vein occlusion
por: Hall J
Publicado: (2016)

Comment on: “Three-year follow-up of ranibizumab treatment of wet age-related macular degeneration: influence of baseline visual acuity and injection frequency on visual outcomes”
por: Kaya A
Publicado: (2016)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa B, et al.
Publicado: (2021)

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2)
por: Jumper JM, et al.
Publicado: (2018)

Intravitreal Aflibercept versus Laser Photocoagulation in Asian Patients with Diabetic Macular Edema: The VIVID-East Study
por: Chen YX, et al.
Publicado: (2020)

Vitreous Reflux Frequency and Intraocular Pressure After First-Time Intravitreal Aflibercept Injections: Comparison of 30- and 32-Gauge Needles
por: Muto T, et al.
Publicado: (2020)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
por: Azuma K, et al.
Publicado: (2018)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
por: Paulose R, et al.
Publicado: (2016)

Risk factors for retinal breaks during macular hole surgery
por: Sakamoto M, et al.
Publicado: (2018)

Complement Factor H Loss in RPE Cells Causes Retinal Degeneration in a Human RPE-Porcine Retinal Explant Co-Culture Model
por: Angela Armento, et al.
Publicado: (2021)

Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials
por: Dugel PU, et al.
Publicado: (2016)

Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options
por: Veritti D, et al.
Publicado: (2021)

Long-term results of combination therapy using anti-VEGF agents and dexamethasone intravitreal implant for retinal vein occlusion: an investigational case series
por: Singer MA, et al.
Publicado: (2016)

Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age
por: Karagiannis D, et al.
Publicado: (2017)

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
por: Michalska-Małecka K, et al.
Publicado: (2016)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
por: Thomas BJ, et al.
Publicado: (2016)

Six-month results of intravitreal ranibizumab for macular edema after branch retinal vein occlusion in a single-center prospective study: visual outcomes and microaneurysm formation
por: Kawamura M, et al.
Publicado: (2018)

Revisiting the Utility of Dilated Fundus Exams in Patients with Neovascular Age-Related Macular Degeneration Receiving Regular Intravitreal Injections
por: Antaki F, et al.
Publicado: (2021)

Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents
por: Ruão M, et al.
Publicado: (2017)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
por: Nixon DR, et al.
Publicado: (2018)